Ditchcarbon
  • Contact
  1. Organizations
  2. Alkermes, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 days ago

Alkermes, Inc.

Company website

Alkermes, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established itself as a leader in the industry, with significant operational presence across North America and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it favourably in the market, with notable achievements in advancing patient care through its proprietary formulations. With a strong emphasis on research and development, Alkermes continues to drive innovation in the biopharmaceutical landscape.

DitchCarbon Score

How does Alkermes, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Alkermes, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

40%

Let us know if this data was useful to you

Alkermes, Inc.'s reported carbon emissions

Alkermes, Inc., headquartered in the US, has reported its carbon emissions data for the years 2015 to 2017. In 2017, the company recorded Scope 1 and 2 emissions of approximately 125,000 kg CO2e per employee, reflecting a decrease from about 140,000 kg CO2e per employee in 2016 and about 179,000 kg CO2e per employee in 2015. This trend indicates a commitment to reducing emissions intensity relative to its workforce. Despite these figures, Alkermes has not disclosed specific Scope 1, 2, or 3 emissions totals, nor has it set formal reduction targets through initiatives such as the Science Based Targets initiative (SBTi). The company is a current subsidiary of Alkermes plc, and its emissions data may be influenced by the broader corporate family context. Alkermes has not outlined any specific climate pledges or reduction initiatives in the available data. However, the company’s focus on emissions per employee suggests an ongoing effort to improve its environmental performance. As the industry increasingly prioritises sustainability, Alkermes may need to establish clearer climate commitments to align with global standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Alkermes, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Alkermes, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Alkermes, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Indivior

US
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated about 17 hours ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Viatris

US
•
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Intra-Cellular Therapies, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 24 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251013.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy